Several established biomarkers such as Telomerase reverse transcriptase (TERT), tumor protein p53 (TP53), Catenin Beta 1 (CTNNB1), AT‐rich interaction domain 1A (ARID1A), and Axis inhibition protein 1 (AXIN1) have been validated for their impact on HCC and related pathways, including PI3K/AKT/mTOR and RAS/RAF/MAPK pathways [8]. The gene discussed is TP53; the disease is hepatocellular carcinoma.